RecruitingNCT06863155

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

Sponsor

Fundación EPIC

Enrollment

500 participants

Start Date

May 6, 2025

Study Type

OBSERVATIONAL

Conditions

Coronary Artery Disease Ischemic Heart Disease

Summary

Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Supraflex Cruz Sirolimus-eluting Stent for people with coronary artery disease and ischemic heart disease. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESupraflex Cruz Sirolimus-eluting Stent

PCI with SupraFlex Cruz® stent in de novo coronary stenosis of patients under chronic oral anticoagulation.

Locations(12)

Hospital General Universitario de Albacete

Albacete, Spain

Hospital Universitario San Juan de Alicante

Alicante, Spain

Hospital General Universitario de Merida

Badajoz, Spain

Hospital General Universitari de Castelló

Castelló, Spain

H.G.U. de Ciudad Real.

Ciudad Real, Spain

Hospital General Universitari d'Elx

Elche, Spain

Hospital Universitario de Canarias

Laguna, Spain

Hospital Doctor Jose Molina Orosa

Las Palmas de Gran Canaria, Spain

Hospital Universitario Puerta de Hierro

Majadahonda, Spain

Hospital Universitario de Navarra

Pamplona, Spain

Hospital General de Fuerteventura

Puerto del Rosario, Spain

Hospital Clinico Universitario Lozano Blesa

Zaragoza, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06863155

Related Trials

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT0677963023 locations

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582902 locations

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT0704519415 locations

CPB and Aortic Cross-Clamp Durations and ICU Length of Stay After CABG Retrospective Observational Cohort Study

NCT077119511 location

Digital Long-term Follow-up of Patients With Coronary Artery Disease: a Randomized Controlled Trial

NCT077203492 locations